Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTE-051 in moderate to severe plaque psoriasis
NCT03358290Phase 2Terminated
- Sponsor
- Akros Pharma Inc.
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of JTE-051 in plaque psoriasis, sponsored by Akros Pharma Inc.. Started Nov 2017; status: terminated.
02
Drugs
JTE-051
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03358290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358290.